We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$28.3M
Cap. Flow
+$26.6M
Cap. Flow %
0.86%
Top 10 Hldgs %
33.83%
Holding
206
New
17
Increased
43
Reduced
39
Closed
34

Top Buys

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$33.8M
2
IDXX icon
Idexx Laboratories
IDXX
+$30.1M
3
GH icon
Guardant Health
GH
+$27.2M
4
AMGN icon
Amgen
AMGN
+$25.7M
5
AZN icon
AstraZeneca
AZN
+$21.2M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$35.4M
2
RMD icon
ResMed
RMD
+$33.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.9M
4
DXCM icon
DexCom
DXCM
+$20.1M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.51%
2 Real Estate 2.72%
3 Industrials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVO
76
Novo Nordisk
NVO
$208B
$9.19M 0.3%
191,406
+94,594
+98% +$4.57M
OHI icon
77
Omega Healthcare
OHI
$14.6B
$9.18M 0.3%
306,433
– –
MTD icon
78
Mettler-Toledo International
MTD
$29B
$9.16M 0.29%
6,650
-3,150
-32% -$4.74M
DOC
79
DELISTED
PHYSICIANS REALTY TRUST
DOC
$8.73M 0.28%
495,733
– –
GTHX
80
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$8.38M 0.27%
624,369
– –
UHS icon
81
Universal Health Services
UHS
$10.3B
$8.3M 0.27%
60,023
– –
MPT
82
Medical Properties Trust
MPT
$2.74B
$8.26M 0.27%
411,743
– –
BSX icon
83
Boston Scientific
BSX
$71.8B
$8.07M 0.26%
185,931
– –
TPTX
84
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$7.93M 0.26%
119,324
– –
NTLA icon
85
Intellia Therapeutics
NTLA
$1.51B
$7.8M 0.25%
58,180
– –
QURE icon
86
uniQure
QURE
$3.04B
$7.59M 0.24%
237,008
+11,087
+5% +$338K
STRO icon
87
Sutro Biopharma
STRO
$413M
$7.56M 0.24%
40,015
– –
SBRA icon
88
Sabra Healthcare REIT
SBRA
$5.18B
$7.52M 0.24%
510,660
– –
SNY icon
89
Sanofi
SNY
$103B
$7.39M 0.24%
153,254
+71,700
+88% +$3.65M
PHG icon
90
Philips
PHG
$25.6B
$7.32M 0.24%
199,498
+130,581
+189% +$4.96M
GRTX
91
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$7.28M 0.23%
898,374
-143,471
-14% -$1.23M
ARVN icon
92
Arvinas
ARVN
$515M
$7.07M 0.23%
85,997
– –
ADUS icon
93
Addus HomeCare
ADUS
$2.18B
$6.67M 0.21%
83,632
+29,395
+54% +$2.55M
APLS
94
DELISTED
Apellis Pharmaceuticals
APLS
$6.45M 0.21%
195,820
+43,282
+28% +$2.43M
A icon
95
Agilent Technologies
A
$39.5B
$6.24M 0.2%
39,625
-12,900
-25% -$2.09M
SNN icon
96
Smith & Nephew
SNN
$13.6B
$6.24M 0.2%
181,710
+74,040
+69% +$2.92M
TEVA icon
97
Teva Pharmaceuticals
TEVA
$40.1B
$5.92M 0.19%
607,651
– –
RVTY icon
98
Revvity
RVTY
$12.9B
$5.8M 0.19%
33,444
-3,650
-10% -$643K
LTC
99
LTC Properties
LTC
$1.99B
$5.78M 0.19%
182,293
– –
FOLD
100
DELISTED
Amicus Therapeutics
FOLD
$5.61M 0.18%
587,277
-34,382
-6% -$352K
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Tekla Capital Management held 206 positions worth $3.11B, up 0.92% from $3.08B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Tekla Capital Management's Q3 2021 filing shows 17 new, 43 increased, 39 reduced and 34 closed positions. Its largest new stake was Rallybio: 288,584 shares worth $37.6M. The largest sale was Elevance Health, an estimated $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2021 buy was Rallybio: 288,584 shares worth $37.6M.
  • Tekla Capital Management added most to Idexx Laboratories in Q3 2021, an estimated $30.1M increase.
  • Tekla Capital Management's biggest Q3 2021 reduction was Elevance Health, cutting an estimated $35.4M.
  • Tekla Capital Management fully exited Iovance Biotherapeutics in Q3 2021, selling an estimated $12.2M.
  • Tekla Capital Management's ten largest holdings make up 34% of its $3.11B portfolio in Q3 2021.
  • Tekla Capital Management opened 17 new positions and closed 34 in Q3 2021.
  • Tekla Capital Management's portfolio value rose 0.92% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.